A growing body of work (including recent preclinical and clinical data) support targeting the HER family for preventing ER-negative and possibly ER-positive breast cancer.
Clearly, approaches for preventing ER-negative, and increased prevention of ER-positive breast cancers would benefit public health. Preventing breast cancer is possible with selective estrogen receptor (ER) modulators and aromatase inhibitors, which reduce the risk of invasive disease by up to 65% (up to 73% for ER-positive and no effect for ER-negative cancer) and the risk of preinvasive disease by up to 50%.
0 kommentar(er)
